Belfast Health and Social Care Trust
caring supporting improving together

FOI/38577

23 October 2026

New patients treated by Belfast Trust's Gastroenterology Department in the latest 3-month period of May, June and July 2026

How many new patients were treated by Belfast Trust's Gastroenterology Department in the latest 3 month period of May, June and July (or the latest 3 months available) with the treatments I have provided below?

If you are able to, could you please provide the split of new patients who received their treatment for Crohn's disease and Ulcerative colitis.

Please can you define a "new patient" as a patient who has received any of the treatments listed below for the first time. If a patient received any of the below treatments before the 1st December 2025 but did not receive any of the treatments between December 2025 and May 2026, they can be classed as a new patient for the purposes of this question.

	Total Gastroenterology Department	Crohn's Disease	Ulcerative Colitis
Adalimumab [Humira]	10	<10	<10
Adalimumab [All Biosimilar]	300	290	10
Etrasimod	0	[redacted]	0
Filgotinib	22		0
Golimumab [Simponi]	<10	0	<10
Golimumab [All Biosimilar]	<10	<10	0
Guselkumab	35	15	20
Infliximab [Remicade]	40	25	15
Infliximab [All Biosimilar]	250	150	100
Mirikizumab	35	<10	34
Ozanimod	<10	[redacted]	0
Risankizumab	70	67	<10
Tofacitinib	<10	[redacted]	0
Upadacitinib	100	60	40
Ustekinumab [Stelara]	<10	<10	0
Ustekinumab [All Biosimilar]	380	280	100
Vedolizumab	130	36	94